Postmenopausal Hormone Therapy Reduces Risk for Some Cancers

Use of hormone therapy for menopause is associated with reduced risks for esophageal, gastric, and colorectal cancers, according to results of a prospective study that were then combined with published studies in a meta-analysis. In this British study of women aged 50 to 64 years, researchers found no significant differences in risk by type of hormone therapy, duration of use, or between past and current users. The reduction in risk, however, was small in comparison to the increased risk of breast cancer that has been attributed to hormone therapy in this population.


Complete study results are available as an accepted manuscript on the website of the International Journal of Cancer (

Related Items
Combination Immunotherapy the New Standard for Patients with Metastatic Melanoma
Walter Alexander
TOP - August 2016, Vol 9, No 3 published on August 3, 2016 in Melanoma, Drug Therapies
Designer Drug” Rociletinib Shows Encouraging Results in Patients with NSCLC and T790M Mutation
Alice Goodman
TOP November 2015 Vol 8 No 4 published on December 3, 2015 in Drug Therapies
New End Points Create Novel Challenges for Health Plans in Oncology Drug Management
James T. Kenney Jr, RPh, MBA
Web Exclusives published on August 25, 2011 in Drug Therapies
Hsp90 Inhibition Counters JAK/STAT-Signaling Diseases
TOP - Daily published on June 1, 2011 in Drug Therapies
Drug Exposure, Response Rates Associated with Higher Doses of Melphalan
Cristi Radford, MS, CGC
Web Exclusives published on May 26, 2011 in Drug Therapies
Pharmacist Review of Palonosetron Use Has Potential to Capture Inappropriate Use and Save Money
Wayne Kuznar
Web Exclusives published on February 17, 2011 in Drug Therapies
Preoperative Anti-HER2 Agents Yield Benefits
Caroline Helwick
Web Exclusives published on December 23, 2010 in Drug Therapies, In the News
Last modified: July 22, 2021